FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898826322> ?p ?o ?g. }

• W2898826322 endingPage "202" @default.
• W2898826322 startingPage "194" @default.
• W2898826322 abstract "ObjectiveTo evaluate the cost-effectiveness of financial incentives for human immunodeficiency virus (HIV) viral suppression compared to standard of care.Study DesignMathematical model of 2-year intervention offering financial incentives ($70 quarterly) for viral suppression (<400 copies/ml3) based on the HPTN 065 clinical trial with HIV patients in the Bronx, NY and Washington, D.C.MethodsA disease progression model with HIV transmission risk equations was developed following guidelines from the Second Panel on Cost-Effectiveness in Health and Medicine. We used health care sector and societal perspectives, 3% discount rate, and lifetime horizon. Data sources included trial data (baseline N = 16,208 patients), CDC HIV Surveillance data, and published literature. Outcomes were costs (2017 USD), quality-adjusted life years (QALYs), HIV infections prevented, and incremental cost-effectiveness ratio (ICER).ResultsFinancial incentives for viral suppression were estimated to be cost-saving from a societal perspective and cost-effective ($49,877/QALY) from a health care sector perspective. Compared to the standard of care, financial incentives gain 0.06 QALYs and lower discounted lifetime costs by $4210 per patient. The model estimates that incentivized patients transmit 9% fewer infections than the standard-of-care patients. In the sensitivity analysis, ICER 95% credible intervals ranged from cost-saving to $501,610/QALY with 72% of simulations being cost-effective using a $150,000/QALY threshold. Modeling results are limited by uncertainty in efficacy from the clinical trial.ConclusionsFinancial incentives, as used in HTPN 065, are estimated to improve quality and length of life, reduce HIV transmissions, and save money from a societal perspective. Financial incentives offer a promising option for enhancing the benefits of medication in the United States." @default.
• W2898826322 created "2018-11-09" @default.
• W2898826322 creator A5010009356 @default.
• W2898826322 creator A5058788810 @default.
• W2898826322 creator A5060445377 @default.
• W2898826322 creator A5060938706 @default.
• W2898826322 creator A5063945368 @default.
• W2898826322 creator A5065911353 @default.
• W2898826322 creator A5068073076 @default.
• W2898826322 creator A5084390255 @default.
• W2898826322 date "2019-02-01" @default.
• W2898826322 modified "2023-10-11" @default.
• W2898826322 title "The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study" @default.
• W2898826322 cites W1497170016 @default.
• W2898826322 cites W173911802 @default.
• W2898826322 cites W1915157409 @default.
• W2898826322 cites W1966780336 @default.
• W2898826322 cites W1979871017 @default.
• W2898826322 cites W1981177608 @default.
• W2898826322 cites W1991541076 @default.
• W2898826322 cites W2000551051 @default.
• W2898826322 cites W2002945998 @default.
• W2898826322 cites W2004873336 @default.
• W2898826322 cites W2014171916 @default.
• W2898826322 cites W2017037891 @default.
• W2898826322 cites W2017736583 @default.
• W2898826322 cites W2020285227 @default.
• W2898826322 cites W2037823404 @default.
• W2898826322 cites W2067100208 @default.
• W2898826322 cites W2075324741 @default.
• W2898826322 cites W2087038904 @default.
• W2898826322 cites W2100430786 @default.
• W2898826322 cites W2115053153 @default.
• W2898826322 cites W2119835296 @default.
• W2898826322 cites W2120953033 @default.
• W2898826322 cites W2122795395 @default.
• W2898826322 cites W2124188134 @default.
• W2898826322 cites W2124229533 @default.
• W2898826322 cites W2127832030 @default.
• W2898826322 cites W2133053181 @default.
• W2898826322 cites W2135785083 @default.
• W2898826322 cites W2138652626 @default.
• W2898826322 cites W2139814250 @default.
• W2898826322 cites W2140789060 @default.
• W2898826322 cites W2144921921 @default.
• W2898826322 cites W2149443374 @default.
• W2898826322 cites W2149446514 @default.
• W2898826322 cites W2149759731 @default.
• W2898826322 cites W2151969385 @default.
• W2898826322 cites W2152505869 @default.
• W2898826322 cites W2154065613 @default.
• W2898826322 cites W2158040892 @default.
• W2898826322 cites W2159578134 @default.
• W2898826322 cites W2159612600 @default.
• W2898826322 cites W2161977186 @default.
• W2898826322 cites W2162935397 @default.
• W2898826322 cites W2167825902 @default.
• W2898826322 cites W2170239385 @default.
• W2898826322 cites W2238552371 @default.
• W2898826322 cites W2273406108 @default.
• W2898826322 cites W2475857717 @default.
• W2898826322 cites W2519603001 @default.
• W2898826322 cites W2586911529 @default.
• W2898826322 cites W2591800518 @default.
• W2898826322 cites W2615682111 @default.
• W2898826322 cites W2620196777 @default.
• W2898826322 cites W2620203957 @default.
• W2898826322 cites W2626716901 @default.
• W2898826322 cites W2716765460 @default.
• W2898826322 cites W2770442016 @default.
• W2898826322 cites W2973759191 @default.
• W2898826322 doi "https://doi.org/10.1016/j.jval.2018.09.001" @default.
• W2898826322 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6362462" @default.
• W2898826322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30711064" @default.
• W2898826322 hasPublicationYear "2019" @default.
• W2898826322 type Work @default.
• W2898826322 sameAs 2898826322 @default.
• W2898826322 citedByCount "17" @default.
• W2898826322 countsByYear W28988263222018 @default.
• W2898826322 countsByYear W28988263222019 @default.
• W2898826322 countsByYear W28988263222021 @default.
• W2898826322 countsByYear W28988263222022 @default.
• W2898826322 countsByYear W28988263222023 @default.
• W2898826322 crossrefType "journal-article" @default.
• W2898826322 hasAuthorship W2898826322A5010009356 @default.
• W2898826322 hasAuthorship W2898826322A5058788810 @default.
• W2898826322 hasAuthorship W2898826322A5060445377 @default.
• W2898826322 hasAuthorship W2898826322A5060938706 @default.
• W2898826322 hasAuthorship W2898826322A5063945368 @default.
• W2898826322 hasAuthorship W2898826322A5065911353 @default.
• W2898826322 hasAuthorship W2898826322A5068073076 @default.
• W2898826322 hasAuthorship W2898826322A5084390255 @default.
• W2898826322 hasBestOaLocation W28988263221 @default.
• W2898826322 hasConcept C112930515 @default.
• W2898826322 hasConcept C126322002 @default.
• W2898826322 hasConcept C127454912 @default.
• W2898826322 hasConcept C160735492 @default.
• W2898826322 hasConcept C162118730 @default.

• next